FDA Approves Atzumi for Acute Treatment of Migraine

We’re thrilled to congratulate Satsuma Pharmaceuticals, Inc. on receiving U.S. FDA approval for Atzumi™ (dihydroergotamine) nasal powder for the acute treatment of migraine in adults—a significant milestone for the millions impacted by migraines nationwide.

At DelRicht Research, we are incredibly proud of our principal investigators and teams, who played a vital role in the research that led to this approval, serving as trusted clinical trial partners across six U.S. site locations. Their expertise and dedication helped bring this fast-acting, innovative treatment to patients through successful enrollment, retention, and participation in pivotal migraine studies.

We’re honored to contribute to the development of groundbreaking therapies that improve patient outcomes and are proud to collaborate with sponsors and CROs advancing neurological care.

Read Satsuma’s full press release here.

Congratulations again to the team at Satsuma on this exciting achievement, and thank you to our dedicated teams and trial participants who helped make this possible!